Success Story: EB-1A Approved Under Premium Processing! Our Expert Team Positioned Liquid Biopsy Research as Field-Trusted Impact
Client’s Testimonial:
"I would like to express my sincere appreciation for the diligence, effort, and careful review that you and your team devoted to my case. Your professionalism and thoroughness were instrumental in achieving approval, and I am truly grateful. I would also like to extend my special thanks to my attorney for her prompt and responsive communication; every inquiry was addressed within 24 hours, which I greatly appreciated. I have already recommended your firm to several friends and colleagues and will continue to do so. Thank you again for your outstanding support.”
On September 24th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Scientist in the Field of Cancer Genetics (Approval Notice).
General Field: Cancer Genetics
Position at the Time of Case Filing: Postdoctoral Scientist
Country of Origin: Iran
Approval Notice Date: September 24th, 2025
Processing Time: 19 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (Chen Immigration Law Associates) is pleased to share an I-140 EB-1A (Alien of Extraordinary Ability) approval for the client, a cancer genetics researcher. Filed under Premium Processing from the start, the case was presented with a clear strategic goal: show not only strong achievements, but a field-verified pattern of impact and trust.
Research Focus
The client has established a specialized research profile in cancer genetics, contributing to the development of molecular tools that support non-invasive disease detection and monitoring while reducing dependence on invasive diagnostic procedures.
The petition also documented the client’s current employment in a U.S.-based pediatric research hospital environment, where the client conducts translational research projects focused on improving outcomes in metastatic cancers and advancing precision-medicine approaches that link molecular signals to treatment decisions. This continuity mattered, since EB-1A requires evidence that the client will continue working in the same area of extraordinary ability.
An Evidentiary Record
For EB-1A, strong metrics are helpful, but they are not automatically decisive. Adjudicators tend to be persuaded when the record shows repeated external validation, meaning the field repeatedly treats the work as worth publishing, worth citing, and worth relying on. We organized the evidence to highlight that pattern and to connect each metric to what it signals in real research practice.
The petition highlighted a record that included:
- 21 peer-reviewed journal articles (11 first-authored or co-first-authored)
- 338 citations to the client’s published body of work
- Funding support connected to the National Institutes of Health (NIH)
Rather than treating citation totals as self-proving, we framed citations as evidence of independent reliance, showing that other researchers have used the client’s findings to inform their own work. The record also included field-normalized context showing that at least one publication achieved notably high citation performance for its publication year in a relevant category, helping an adjudicator interpret influence beyond raw counts.
Peer-Recognized Authority
We also emphasized that the client is not only producing research, but is trusted to evaluate the work of others, a meaningful signal because journals typically invite reviewers they view as technically reliable and well-positioned to assess rigor and significance. The record reflected at least 17 completed peer reviews, which we presented as evidence of sustained professional trust and standing within the field.
Peer-Recognized Authority
To corroborate the objective record, the petition included four letters of recommendation from established experts, including independent advisory perspectives from experts familiar with the client’s work through reading and relying on published research. Strategically, these letters were used to connect the client’s contributions to broader significance in cancer genetics and to reinforce why the client’s diagnostic and therapeutic research direction has been influential.
One expert noted that “...[Client’s] work is of great value, and that she is an irreplaceable presence in the research sphere.”
The Result
The EB-1A I-140 petition was approved under Premium Processing in just 19 days. This outcome reflects a case presentation that framed the client’s achievements as more than strong metrics, specifically as sustained, field-recognized impact in cancer genetics supported by selective publication success, independent citation reliance, peer-review trust, major research support, and expert testimony.